BioWorld: The founders of the U.K.-listed gene editing technology firm Horizon Discovery plc, Alberto Bardelli and Chris Torrance, have re-emerged in a new startup that has a therapeutic focus.
30.11.2017
Neophore to prod cancer into neoantigen expression by targeting DNA mismatch repair
More news
16.12.2024
Neophore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international p…
22.05.2024
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…
11.04.2024
NeoPhore presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.
The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…